Purpose: Lacrimal gland tumours constitute a wide spectrum of neoplastic lesions that are histologically similar to tumours of the salivary gland. In the salivary gland, pleomorphic adenoma (PA) is frequently characterized by recurrent chromosomal rearrangements of the PLAG1 and HMGA2 genes, a genetic feature retained in carcinoma ex pleomorphic adenoma (ca-ex-PA) that makes it possible to distinguish ca-ex-PA from de novo carcinomas. However, whether PLAG1 and HMGA2 gene rearrangements are found in lacrimal gland PA and ca-ex-PA is not known. Methods: Twenty-one lacrimal gland PAs and four ca-ex-PAs were retrospectively reviewed and subjected to break-apart fluorescence in situ hybridization (FISH) for rearrangements of the PLAG1 gene. Cases without PLAG1 abnormalities were subjected to HMGA2 break-apart FISH. Immunohistochemical staining for PLAG1 and HMGA2 protein was performed and correlated with gene status. Results: Sixteen of 21 PAs showed rearrangement of PLAG1 and were all positive for PLAG1 protein. Two of the remaining five PAs showed rearrangement of HMGA2 and were the only cases positive for HMGA2 with immunohistochemistry. The three FISH-negative PAs expressed PLAG1 protein. All four ca-ex-PAs showed rearrangement of PLAG1 and expressed PLAG1 protein. None of the de novo carcinomas showed rearrangement of either of the two genes or expression of the two proteins. Conclusion: Rearrangement of PLAG1 and HMGA2 and expression of the corresponding proteins are frequent and specific findings in lacrimal gland PA and ca-ex-PA. The mechanism for PLAG1 overexpression in FISH-negative PAs is yet to be clarified.
Introduction
Pleomorphic adenoma (PA) is the most frequent tumour of the lacrimal gland and is histologically composed of a dual cell population of ductal -and myoepithelial cells in a chondromyxoid stroma. Clinically, PA is characterized by its tendency to recur and its ability to undergo malignant transformation to carcinoma ex pleomorphic adenoma (ca-ex-PA). These features are shared with PA of the salivary gland, in which the genetics have been extensively characterized (Weinreb 2013; Andreasen et al. 2016a,b) . Here, mutually exclusive aberrations of the Pleomorphic Adenoma Gene 1 (PLAG1) on 8q12 and High Mobility Group AT-hook 2 (HMGA2) gene on 12q14 are pathognomonic for PA and ca-ex-PA among salivary gland tumours (Sandros et al. 1990; Bullerdiek et al. 1993; Geurts et al. 1997; Kas et al. 1997) . Overexpression of these two developmentally regulated transcription factors is the result of gene fusions involving one of several different partner genes (Table 1 ; Kas et al. 1997; Geurts et al. 1997; Stenman 2005) . Whether these genetic characteristics extend to include lacrimal gland PA and ca-ex-PA is not known.
The prognosis of salivary gland carcinomas in general depends on the disease stage, while the clinical outcome of ca-ex-PA also depends on the degree of invasion beyond the maternal PA (Seethala 2009; Antony et al. 2012; Rito & Fonseca 2016; Williams et al. 2017) . While the extent of invasion associated with adverse outcome has been debated, intracapsular (i.e. in situ) and minimally invasive ca-ex-PA (<1.5-6 mm) are indolent, while widely invasive tumours are high-grade with a poor prognosis (Di Palma 2013; Rito & Fonseca 2016) . Thus, separating ca-ex-PA from de novo carcinoma is not merely a nosological triviality in the salivary gland, and this may also be the case in the lacrimal gland.
To clarify whether the relationship between PA and ca-ex-PA from the lacrimal gland extends to include involvement of these two genes, we genetically characterize a large material with fluorescence in situ hybridization (FISH). In addition to identifying PAs with variant morphologies, this could prove to be a valuable tool in separating ca-ex-PA from de novo carcinomas, thereby serving as molecular markers for investigating the degree of invasiveness as a prognostic tool in lacrimal gland ca-ex-PA.
Materials and Methods

Patient material
A total of 21 primary PAs of the lacrimal gland were included along with four caex-PAs (two mucoepidermoid carcinomas, one adenocarcinoma not otherwise specified (NOS) and one myoepithelial carcinoma) with available formalin-fixed paraffin-embedded (FFPE) tissue. As controls, one de novo mucoepidermoid carcinoma, two adenocarcinoma NOS and five adenoid cystic carcinomas were included for comparison. All cases were histologically reviewed to confirm the diagnosis. Patient information was retrieved from patient files and staged accordingtotheAJCC8th edition (White et al. 2017) . The study adhered to the tenets of the Declaration of Helsinki and hasbeenapprovedbytheRegionalEthics Committee (Journal No. H-6-2014-086) and the Danish Data Protection Agency (Journal No. REG-94-2014) .
Histopathology and immunohistochemistry
Five-micron FFPE sections were stained using the Ventana autostaining system (Ventana Medical Systems Inc., Tucson, AZ, USA) using primary antibodies for pan-cytokeratin (clone AE1/ AE3, Dako, Glostrup, Denmark), p63 (clone 4A4; Roche, Hvidovre, Denmark), PLAG1 (clone 3B7; Novus Biologicals, Littleton, CO, USA) and HMGA2 (clone D1A7; Cell Signaling Technology Inc., Beverly, MA, USA) as previously described (Andreasen et al. 2015) . Positive controls suggested in respective datasheets were used, and the expected reaction and subcellular site were in accordance with these. Negative controls omitting the primary antibodies were carried out. Tumours were diagnosed according to the World Health Organization Classification of Tumours (Slootweg 2017 ).
Fluorescence in situ hybridization
All cases were subjected to FISH using break-apart probes for PLAG1, and PLAG1-negative cases were investigated with HMGA2 and NFIB (all from Empire Genomics, Buffalo, NY, USA) break-apart probes according to the manufacturers' protocol using the HYBrite platform (Abbott Molecular, Des Plaines, IL, USA; Andreasen et al. 2017a) . After hybridization, nuclei were counterstained with DAPI II (ZytoVision GmbH, Bremerhaven, Germany). One hundred nuclei were counted when possible, and only nuclei in which the entire nuclear membrane could be visualized were scored. The rearrangement was defined as split signals ≥10% of the nuclei. Parotid gland PAs with known PLAG1 or HMGA2 rearrangements and adenoid cystic carcinoma with NFIB rearrangement were used as positive controls (Andreasen et al. 2017a) .
Results
Clinicopathologic characteristics
Patients with lacrimal gland PA were female in 63.6% of cases, with a median age of 46.5 years (range: 13-81), and patients with ca-ex-PA were female in 75% of cases, with a median age of 43 years (range: 31-65; Fig. 1A,B) . Macroscopically, all PAs were well circumscribed, without macroscopical evidence of extracapsular invasion. On microscopical examination, all PAs were uniformly benign with low mitotic activity and no evidence of in situ malignant transformation (Fig. 1C) . All PAs were biphasic tumours with ductal and myoepithelial components in variable proportions (Fig. 1D) . In contrast, two ca-ex-PAs invaded the surrounding lacrimal gland tissue (T1N0M0 and T2N0M0), whereas two were widely invasive into orbital soft tissue (both T4N0M0; Fig. 1E ). Two ca-ex-PAs arose in recurrent PA. The carcinoma components were grade III mucoepidermoid carcinoma in two cases, highgrade adenocarcinoma NOS in one case and myoepithelial carcinoma in the remaining case (Fig. 1E,F) .
Fluorescence in situ hybridization results and immunohistochemical findings
Sixteen of 21 (76.2%) PAs showed the presence of copy-neutral PLAG1 rearrangement ( Fig. 2A) . Among the five PLAG1-negative cases, two had a copyneutral rearrangement of HMGA2 (9.5%; Fig. 2B ). None of these showed rearrangements of NFIB. The remaining three PAs had intact signals for all three probes. All cases were histologically similar, regardless of genetic status. De novo lacrimal gland carcinomas all showed intact and copy-neutral PLAG1 and HMGA2 signals.
The PLAG1-rearranged cases were intensely PLAG1-positive and HMGAnegative by immunohistochemistry (Fig. 2C) . The two HMGA2 rearranged cases were both intensely HMGA2-positive and one also weakly positive for PLAG1 (Fig. 2D) . All three FISHnegative cases were intensely PLAG1-positive and HMGA2-negative.
Discussion
Pathognomonic gene fusions are well described among salivary gland tumours, and several of these along with other genetic characteristics are known to be mutual with tumours of the lacrimal gland (Andreasen et al. 2015 (Andreasen et al. , 2016a (Andreasen et al. ,b, 2017b . With this study, PLAG1 and HMGA2 translocationsareaddedtothislist,asthey are recurrent and specific findings for PA and ca-ex-PA in lacrimal gland tumours. Importantly, this provides a biological rationale as well as a molecular marker for investigating the prognostic value of the extent of invasiveness in lacrimal gland caex-PA. This has the potential to more accurately stratify patients according to tumour aggressiveness and to rationally select patients requiring more extensive surgical resection and adjuvant therapy (Tortoledo et al. 1984) .
Previous studies of lacrimal gland PA using conventional karyotyping have identified abnormalities in the chromosomal regions harbouring PLAG1 and HMGA2; however, this method lacks the ability to identify the specific genes involved (Jin et al. 1994) . As in the salivary gland counterpart, these aberrations seem to be fundamental in tumourigenesis of the majority of PAs and were retained after malignant transformation to ca-ex-PA in all four cases presented here. This possibly reflects fundamentally different molecular backgrounds in ca-ex-PA and histologically identical malignancies arising de novo, which is known to be the case in the salivary gland (Chiosea et al. 2016; Dalin et al. 2017) . With the emergence of targeted therapies, this refinement of molecular taxonomy becomes increasingly relevant.
Rearrangement of PLAG1 is not reserved for tumours of the lacrimal and salivary glands, but recurrent PLAG1 rearrangements have recently been identified in a subset of cutaneous myoepitheliomas, specifically in a subset closely resembling PA with ducts and/or chondromyxoid stroma (Antonescu et al. 2013 ). Thus, a pronounced phenotype-genotype correlation seems to be conferred by PLAG1 activation in tumours at these sites, analogous to the role of MYB in adenoid cystic carcinoma in the same three locations (Persson et al. 2009a; von Holstein et al. 2013; North et al. 2015) .
Immunohistochemical staining of the PLAG1 and HMGA2 protein has previously been demonstrated in lacrimal gland PA, and even one case that was positive for both stains was recently reported (Mendoza et al. 2013; Jakobiec et al. 2017 ). In the salivary gland, these immunohistochemical stainings are known to be a far from perfect surrogate marker for the translocation status of PLAG1 as well as HMGA2 (DebiecRychter et al. 2001; Bahrami et al. 2012; von Holstein et al. 2014) . Here, we confirm this to also be the case in lacrimal gland PA, as the majority of FISH-negative cases were intensely PLAG1-positive. One possible mechanism for the apparently FISH-negative PAs to express PLAG1 protein is intrachromosomal rearrangementsofgenes in proximity to PLAG1 or HMGA2 that are not possible to identify with FISH, which is the case in salivary gland PA (Table 1; Geurts et al. 1997; Kas et al. 1997; Geurts et al. 1998; Voz et al. 1998; Asp et al. 2006; Persson et al. 2008 Persson et al. , 2009b . Indeed, the PLAG1-FGFR1 fusion characterizes a large subset of PAs without PLAG1 rearrangements detectable by FISH (El Hallani et al. 2017) . Also, NFIB is a known fusion partner with HMGA2 but NFIB showed intact signals in both HMGA2-rearranged PAs (Geurts et al. 1998) . However, the underlying mechanism for our three FISHnegative and PLAG1-and HMGA2-negative PA remains to be clarified.
In conclusion, we describe rearrangements of PLAG1 and HMGA2 to be frequent findings in PA and ca-ex-PA akin to their salivary gland counterparts and as being useful in separating ca-ex-PA from de novo lacrimal gland carcinomas. Occasional discrepancy between the expression of PLAG1 and HMGA2 protein and genetic status as determined by FISH warrants further investigation to identify the underlying mechanism in these tumours.
